Colchicine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Colchicine Availability in 2026

Colchicine remains a cornerstone medication across multiple specialties — from rheumatology and primary care to cardiology and emergency medicine. Yet your patients may be telling you they can't fill their prescriptions. While Colchicine is not on the FDA's official Drug Shortage Database as of early 2026, intermittent pharmacy-level stock-outs continue to affect patients nationwide.

This briefing covers the current supply landscape, prescribing considerations, cost and access challenges, and practical tools to help your patients get the medication they need.

Timeline: How We Got Here

Understanding Colchicine's supply challenges requires context:

• Pre-2009: Colchicine was available as an inexpensive, unapproved generic for decades — often under $0.10 per tablet
• 2009: FDA approved Colcrys (Takeda) under the Unapproved Drugs Initiative, granting market exclusivity
• 2010–2011: FDA ordered removal of unapproved colchicine products; Colcrys became the sole U.S. formulation; prices increased approximately 50-fold
• 2014: Mitigare (Hikma) approved as a 0.6 mg capsule for gout prophylaxis
• 2019: Gloperba oral solution approved for gout prevention
• 2023: Lodoco (0.5 mg) approved for cardiovascular risk reduction in adults with established atherosclerotic disease — a significant expansion of the patient population
• 2024–2026: Generic competition has improved, but the total number of manufacturers remains limited, and demand continues to grow across indications

Prescribing Implications

Drug Interactions Require Vigilance

Colchicine has a narrow therapeutic index, and drug interactions remain a leading cause of serious adverse events, including fatalities. Key interactions to monitor:

• Contraindicated combinations (in renal/hepatic impairment): Strong CYP3A4 inhibitors (Clarithromycin, Ketoconazole, Itraconazole, Ritonavir, Atazanavir, Cobicistat) and P-glycoprotein inhibitors (Cyclosporine)
• Dose adjustment required: Moderate CYP3A4 inhibitors (Erythromycin, Fluconazole, Diltiazem, Verapamil)
• Increased myopathy risk: HMG-CoA reductase inhibitors (particularly when combined with Colchicine in cardiovascular patients now on Lodoco)

With the expansion of Colchicine use into cardiology — where patients are commonly on statins, calcium channel blockers, and other interacting medications — careful medication reconciliation is more important than ever. For a comprehensive interaction reference, see Colchicine Drug Interactions: What to Avoid.

Renal and Hepatic Considerations

Patients with CrCl < 30 mL/min are at substantially higher risk for colchicine toxicity. In these patients, dose reduction is mandatory, and concurrent use of CYP3A4/P-gp inhibitors is contraindicated. Dialysis patients on Colchicine require particularly careful monitoring. Hepatic impairment (Child-Pugh C) similarly contraindicates use with interacting drugs.

Monitoring

Consider periodic CBC monitoring, especially in patients on chronic Colchicine therapy, to detect early signs of myelosuppression. Monitor for neuromuscular symptoms (weakness, numbness, tingling) that may indicate toxicity.

Current Availability Picture

The supply landscape in 2026:

• Generic Colchicine 0.6 mg tablets: Multiple manufacturers, but supply can be uneven across wholesalers and regions
• Generic Colchicine 0.6 mg capsules: Available as generic Mitigare equivalents
• Colcrys (brand, Takeda): Generally available but at higher cost
• Mitigare (brand, Hikma): Available; consider when tablet formulation is out of stock
• Gloperba (oral solution, Scilex): Niche product; useful for patients who cannot swallow tablets/capsules
• Lodoco (0.5 mg, Agepha): Newer to market; availability expanding but not universal

When patients report they can't find Colchicine, it's often a specific manufacturer or formulation that's out of stock — not all formulations simultaneously. Specifying "substitution permitted" and noting acceptable alternatives on the prescription can give pharmacists more flexibility.

Cost and Access Challenges

Cost remains a significant access barrier for many patients:

• Retail cash price: $150–$250 for 30 generic tablets (0.6 mg)
• With discount coupons: $8–$15 for the same quantity
• Brand Colcrys: $300+ for 30 tablets without insurance
• Insurance coverage: Most plans cover generic on Tier 2–3 with $10–$40 copays; brand may require prior authorization

For patients struggling with cost, direct them to discount coupon platforms (GoodRx, SingleCare) and patient assistance programs. Takeda's Help at Hand program provides Colcrys at no cost to eligible uninsured patients. More details in our provider guide to helping patients save money on Colchicine.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder is a real-time pharmacy stock search tool that helps patients (and providers) locate which pharmacies currently have a medication in stock. Consider recommending it to patients at the point of prescribing, especially for medications with known availability challenges.

Workflow Integration

For practices seeing frequent Colchicine availability issues, consider these workflow adjustments:

• Include availability notes in patient after-visit summaries (e.g., "If your pharmacy is out of Colchicine, visit medfinder.com/providers to find a pharmacy with stock")
• Maintain a short list of local independent pharmacies that reliably stock Colchicine
• Use e-prescribing to send prescriptions to mail-order pharmacies for chronic use patients
• When prescribing, write "generic substitution permitted" and consider adding a backup medication order in case Colchicine is unavailable

Alternative Prescribing

When Colchicine is unavailable, evidence-based alternatives by indication:

• Acute gout flare: Indomethacin 50 mg TID (tapering), Naproxen 750 mg then 250 mg q8h, or Prednisone 30–40 mg/day for 5 days
• Gout prophylaxis: Low-dose Naproxen 250 mg/day or low-dose Prednisone 5–7.5 mg/day during ULT initiation
• Recurrent pericarditis: NSAIDs (Ibuprofen, Indomethacin) ± Prednisone taper; Anakinra or Rilonacept for refractory cases
• FMF: No direct oral alternative; Anakinra or Canakinumab for colchicine-resistant cases (specialist referral recommended)

A more detailed patient-facing guide is available at Alternatives to Colchicine.

Looking Ahead

Several factors may improve Colchicine access in the coming years:

• Additional generic manufacturers entering the market
• Growing awareness of availability challenges prompting better pharmacy stocking
• Development of new anti-inflammatory agents for gout and cardiovascular disease
• Expanded use of digital tools like Medfinder to connect patients with available stock

However, providers should anticipate that intermittent supply challenges will continue in the near term, given the limited manufacturer base and expanding indications.

Final Thoughts

Colchicine supply in 2026 is stable at the macro level but unpredictable at the pharmacy counter. Providers play a critical role in helping patients navigate availability challenges — whether by recommending real-time stock tools, prescribing with flexibility, or having alternative regimens ready to go.

For more clinical resources and provider tools, visit medfinder.com/providers.